Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.
Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.
复制标题
DOI：
10.1158/1078-0432.ccr-08-1026
复制
发表时间：
2008-11-01
期刊：
影响因子：
--
通讯作者：
Hjalgrim H
中科院分区：
文献类型：
--
作者：
Biggar RJ;Johansen JS;Smedby KE;Rostgaard K;Chang ET;Adami HO;Glimelius B;Molin D;Hamilton-Dutoit S;Melbye M;Hjalgrim H
血清炎症标志物YKL-40和IL-6水平在许多情况下都升高，包括癌症。我们检测了霍奇金淋巴瘤（HL）患者的血清YKL-40和IL-6水平，这是一种对相对较少的肿瘤细胞有强烈免疫反应的肿瘤，尤其是结节性硬化HL。我们分析了丹麦和瑞典的HL事件患者（N=470）和丹麦的人群对照（YKL-40患者N= 245； IL-6患者N= 348）。ELISA检测血清YKL-40和IL-6水平，经年龄和性别调整后，对对数转换数据进行线性回归分析。与对照组相比，HL患者血清中YKL-40和IL-6水平升高（YKL-40: 3.6倍，IL-6: 8.3倍，均p<0.0001）。在治疗前HL患者（N=176）的样本中，YKL-40水平与晚期（YKL-40的ptrend为0.0001，IL-6的ptrend为0.013）和B型症状相关，但在结节硬化和混合细胞亚型、EBV状态、年轻（<45岁）和老年患者中，水平相似。治疗开始后不久检测的患者血清YKL-40和IL-6水平显著低于治疗前患者，但即使在治疗开始后6个月，血清YKL-40和IL-6水平仍显著高于对照组。在死亡患者（N=12）中，治疗前YKL-40和IL-6水平均高于幸存者，但无统计学意义。血清YKL-40和IL-6水平在未治疗的HL患者和晚期HL患者中升高，但在HL组织学上没有显著差异。治疗后，血清水平明显降低。
Serum levels of the inflammatory markers YKL-40 and IL-6 are increased in many conditions, including cancers. We examined serum YKL-40 and IL-6 levels in patients with Hodgkin lymphoma (HL), a tumor with strong immunologic reaction to relatively few tumor cells, especially in nodular sclerosis HL. We analyzed Danish and Swedish patients with incident HL (N=470) and population controls from Denmark (N= 245 for YKL-40; N= 348 for IL-6). Serum YKL-40 and IL-6 levels were determined by ELISA, and log-transformed data were analysed by linear regression, adjusting for age and sex. Serum levels of YKL-40 and IL-6 were increased in HL patients compared to controls (YKL-40: 3.6-fold, IL-6: 8.3-fold; both p<0.0001). In samples from pre-treatment HL patients (N=176), levels were correlated with more advanced stages (ptrend 0.0001 for YKL-40 and 0.013 for IL-6) and in those with B symptoms, but levels were similar in nodular sclerosis and mixed cellularity subtypes, by EBV status, and in younger (<45 years old) and older patients. Patients tested soon after treatment onset had significantly lower levels than pre-treatment patients, but even >6 months after treatment onset, serum YKL-40 and IL-6 levels remained significantly increased, compared to controls. In patients who died (N=12), pre-treatment levels for both YKL-40 and IL-6 were higher than in survivors, although not statistically significantly. Serum YKL-40 and IL-6 levels were increased in untreated HL patients and those with more advanced stages but did not differ significantly by HL histology. Following treatment, serum levels were significantly lower.